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BACKGROUND: High-risk human papillomaviruses (HR-HPVs) can be detected in a proportion of non-melanoma skin cancers. Data on
prevalence are inconclusive, but are essential to estimate the relevance of HR-HPV, particularly with regard to prophylactic HPV
vaccines for skin cancer prevention.
METHODS: High-risk human papillomavirus DNA was investigated in 140 non-melanoma skin lesions from 54 immunocompetent
patients and 33 immunosuppressed renal allograft recipients. Expression of p16
INK4a, a marker for HR-HPV oncogene expression in
the uterine cervix, and of p53 and pRB was evaluated immunohistochemically.
RESULTS: The highest prevalence of HR-HPV was found in squamous cell cancer (SCC) (46.2% (6 out of 13) in immunosuppressed
and 23.5% (4 out of 17) in immunocompetent patients). High-risk human papillomavirus positivity was accompanied by diffuse
p16
INK4a expression in most SCC (Po0.001) and basal cell cancers (P¼0.02), while almost all SCC in situ were p16
INK4a positive
irrespective of HR-HPV presence (P¼0.66). Diffuse p16
INK4a expression was associated with lack of pRB expression (P¼0.001). p53
was strongly expressed in 40.0% (56 out of 140) of the lesions irrespective of HR-HPV presence.
CONCLUSION: High-risk human papillomavirus can be detected in lesions of keratinised squamous epithelia. The association of
HR-HPV with diffuse p16
INK4a expression might indicate HR-HPV oncogene expression in a proportion of lesions. Overexpression of
p53 suggests p53 pathway alterations in HR-HPV-positive and -negative lesions.
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Non-melanoma skin cancer (NMSC) is the most frequent cancer
type in fair-skinned populations and includes basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC) (Madan et al, 2010).
The main risk factor is sun exposure, indicating that UV light-
induced mutations have an important role in the carcinogenesis of
NMSC (Ramos et al, 2004). Several other factors have been suggested
to be involved in NMSC pathogenesis, in particular infectious agents
(Nindl and Rosl, 2008). The increased incidence of NMSC in immuno-
suppressed compared with immunocompetent individuals (Grulich
et al, 2007) suggests a central role of the immune system. In the
general population, BCC accounts for approximately three fourths
and SCC for one fourth of all NMSC cases. Compared with immuno-
competent patients, the BCC/SCC ratio shifts towards SCC in renal
transplant recipients, and the frequency of multiple, more aggressive
lesions is high (Euvrard et al,2 0 0 3 ) .
Basal cell carcinomas and SCCs of the skin are both keratinocyte-
derived tumours which show marked differences in clinical and histo-
pathological properties and most likely also in their aetiopathogenesis
(Madan et al, 2010). Basal cell carcinomas are typically slow growing,
locally invasive tumours that rarely metastasise (Rubin et al, 2005).
By contrast, SCCs tend to be faster growing, locally invasive tumours
with metastatic potential (Alam and Ratner, 2001). The molecular
events taking place in BCC and SCC carcinogenesis are most likely
heterogenic, and current data argue for a multi-step process frequently
involving UV-induced p53 mutations (Boukamp, 2005).
Human papillomavirus DNA of various genotypes has been
detected in NMSC (de Villiers et al, 1997), but its role in NMSC
carcinogenesis is unclear (Pfister, 2003; Nindl et al, 2007). In 30 to
over 80% of NMSC and their precursor lesions, cutaneous and in
particular epidermodysplasia verruciformis-associated HPV types
have been detected (Forslund et al, 2003; Iftner et al, 2003; Nindl
et al, 2004). Some studies report a higher HPV prevalence in
lesions from immunosuppressed patients (Harwood et al, 2000;
Stockfleth et al, 2004). Oncogenic high-risk HPV (HR-HPV) types,
particularly HPV16, which are causally linked to the development
of anogenital cancers and some head and neck cancers (zur
Hausen, 2009), have been detected in 2–50% of NMSC and SCC
in situ of the skin (Bowen’s disease) (Harwood et al, 2000; Iftner et al,
2003; Nindl et al, 2004). Data on active viral oncogene expression and
on differences in HR-HPV prevalence between immunosuppressed
and immunocompetent patients are inconclusive.
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mation of mucosal squamous epithelial cells by inactivation of p53
and pRB once viral oncogenes E6 and E7 are expressed (Scheffner
et al, 1990). High-risk human papillomavirus oncogene expression
in cervical squamous epithelium is accompanied by strong nuclear
and/or cytoplasmic diffuse overexpression of the cellular cyclin-
dependent kinase inhibitor p16
INK4a. In contrast, in transiently
HR-HPV-infected cervical epithelia, in which HPV oncogene
expression is low, no diffuse p16
INK4a expression is detectable
(Sano et al, 1998; Klaes et al, 2001).
We here report evaluation of HR-HPV positivity in multiple
invasive NMSC and non-invasive dysplastic epithelial skin
lesions (SCC in situ, keratoacanthoma (KA)) from immunosup-
pressed renal allograft recipients and immunocompetent patients.
High-risk human papillomavirus status was correlated with
expression of p16
INK4a, pRB, and p53. Gaining more insight into
the expression status of cell cycle regulators in association with
HR-HPV might help to estimate the relevance of HR-HPV in
skin cancer tumour biology in general and particularly in
transplant recipients with multiple non-melanoma skin lesions.
This is of high relevance for estimating the benefit of prophylactic
HPV vaccination for skin cancer prevention in the immunosup-
pressed. Besides viral infections, bacterial colonisation has
attracted attention in cancer biology and might contribute to
carcinogenesis particularly in immunocompromised conditions.
Therefore, in addition to HR-HPV DNA prevalence, the presence
of Staphylococcus aureus infection in the skin lesions was
investigated. A significant association of S. aureus infection with
SCC of the skin has been recently reported (Kullander et al, 2009).
Although a causal role of S. aureus infection in development or
progression of NMSC is not proven, the finding warrants further
investigation, especially in multiple tumours from transplant
recipients.
MATERIALS AND METHODS
Patients and tumour specimens
A consecutive collection of invasive NMSC and/or non-invasive
non-melanoma epithelial skin lesions was obtained from renal
allograft recipients treated in the Department of Nephrology at the
University Hospital Heidelberg, Germany. Inclusion criteria were
age 418 years, no history of autoimmune disease requiring
additional immunosuppression, no history of other malignancies,
at least one renal transplantation, regular follow-up visits at the
renal outpatient clinic of the University Hospital Heidelberg, one
or more invasive NMSC or non-invasive epithelial skin dysplasia
located at non-anogenital sites diagnosed not earlier than 1 year
after transplantation, and stable renal allograft function (estimated
glomerular filtration rate (eGFR) 430mlmin
 1). Invasive NMSC
comprised SCC and BCC and non-invasive epithelial skin lesions
comprised SCC in situ (also termed as Bowen’s disease in the
literature), KA, and actinic keratosis.
All renal allograft recipients had regular skin examination for
malignoma and non-invasive epithelial skin lesions by a derma-
tologist at least once per year. Archival formalin-fixed, paraffin-
embedded tissue of excised NMSC or non-invasive epithelial skin
lesions was used in this study.
A cross-sectional cohort of patients with invasive NMSC or non-
invasive epithelial skin lesions without known immunosuppres-
sion and with regular renal function (eGFR 480mlmin
 1) served
as controls. These patients were selected from the Department of
Dermatology at the University Hospital Heidelberg based on the
dermatopathology diagnosis to match the frequencies of different
types of lesions with the immunosuppressed cohort.
The institutional Ethics Committee approved the protocol;
informed consent was obtained from all enrolled patients.
Microdissection and DNA extraction from tumour tissue
Formalin-fixed, paraffin-embedded tissue sections were stained
with hematoxylin and eosin (H&E). Neoplastic tissue was
morphologically identified under the light microscope and
manually microdissected. DNA was extracted using the DNeasy
Blood and Tissue kit (Qiagen, Hilden, Germany). The DNA was
used for HPV testing and detection of S. aureus.
Detection of HR-HPV DNA
High-risk human papillomavirus detection and genotyping were
done using a multiplex test based on the Luminex technology
(Multimetrix, Heidelberg, Germany) allowing for standardised
detection and typing of the high-risk types HPV16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 68, 73, and 82. PCR was performed using
the supplied primers for amplification of HPV L1 (Schmitt et al,
2006) and b-globin to ensure DNA integrity. From samples with
negative b-globin amplification, DNA extraction was repeated from
additional tumour sections to increase DNA yield. To monitor
potential HR-HPV DNA contamination, formalin-fixed, paraffin-
embedded tissues from colon adenomas were processed as
negative controls throughout the complete procedure from tissue
cutting, microdissection, DNA extraction, and genotyping.
Detection of S. aureus
Staphylococcus aureus was detected by PCR amplification of the
S. aureus nuc gene using previously published primers, forward
50-GCGATTGATGGTGATACGGTT-30 and reverse 50-AGCCAAGCC
TTGACGAACTAAAGC-30, resulting in a 263-bp product (Brakstad
et al, 1992; Kullander et al, 2009). PCR products were further
analysed by DNA sequencing to confirm the nuc gene sequence.
Immunohistochemistry for p16
INK4a, pRB, and p53
expression
For immunohistochemical analyses, 2mm sections from formalin-
fixed, paraffin-embedded tissues were used. p16
INK4a expression
was detected using the CINtec Histology kit (mtm Laboratories,
Heidelberg, Germany) according to the manufacturer’s instruc-
tions. For p53 and pRB staining, antigen retrieval was performed
in citrate buffer. Mouse monoclonal antibodies directed against
p53 (clone DO-7, Dako, Glostrup, Denmark) and pRB (clone
G3–245, BD Pharmingen, Franklin Lakes, NJ, USA) were used.
Visualisation was done using the Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA, USA) and 3,3-diaminobenzidine
(DAB) chromogen (Dako). The sections were counterstained with
hematoxylin (Dako).
Lesions were categorised according to p16
INK4a expression as
(a) positive for a diffuse pattern of nuclear and/or cytoplasmic
p16
INK4a expression, beginning in the basal or parabasal layer and
variably reaching intermediate and superficial cell layers, in
analogy to squamous epithelial lesions at the uterine cervix
(Klaes et al, 2001) and (b) negative for a diffuse p16
INK4a
expression. Lesions classified as negative showed either a focal
staining of single epithelial cells or were completely negative for
p16
INK4a expression.
p53 and pRB expression of the lesions were categorised into
three groups according to the proportion of tumour cells showing
nuclear expression: (1) negative to very low (o10% of tumour
cells), (2) moderate (10–50% of tumour cells), and (3) strong
(450% of tumour cells).
Statistical data analysis
Results were calculated for all analysed skin lesions including all
tumours from patients who had multiple tumours. Additionally,
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separately. Parametric variables are given as mean±s.d., and non-
parametric variables as median and range. Frequency distributions
are provided for categorical variables. Fisher’s exact test or
Student’s t-test was used to test the association between the
parameters HPV status, p16
INK4a/p53/pRB protein expression,
immune status, age, gender, and sun exposure. Two-sided P-values
o0.05 were considered as statistically significant. Associations
were tested for separate strata by Breslow–Day test for homo-
geneity of odds ratios and Chochran–Mantel–Haenszel test for
conditional independence. An association was considered inde-
pendent from the applied strata when Breslow–Day test and
Chochran–Mantel–Haenszel test retrieved P-values 40.05. Data
analyses were carried out using SPSS (v16.0) software (SPSS,
Munich, Germany).
RESULTS
Patient and skin lesion characteristics
Fifty-four renal allograft recipients with non-melanoma skin
lesions recorded in the clinical database fulfilled the inclusion
criteria. From 34 patients (25 male, 9 female; median age of 67
(44–75) years) with a total number of 79 non-melanoma skin
lesions, tumour tissue was available. In addition, 62 non-
melanoma skin lesions from 54 immunocompetent controls
(36 male, 18 female; median age 71 (43–87) years) were included
in the present study (Table 1; Figure 1). All immunosuppressed
and immunocompetent patients were Caucasian and had skin type
Fitzpatrick II or III.
One patient with actinic keratosis was excluded from further
analyses. Histology evaluation of the 78 skin biopsies of the
remaining 33 immunosuppressed patients revealed 13 invasive
SCC, 35 BCC, 24 SCC in situ, and 6 KA. From 54 immunocompe-
tent controls, 17 invasive SCC, 18 BCC, 17 SCC in situ, and 10 KA
were analysed. Lesions diagnosed as KA were non-invasive
dysplastic squamous cell alterations of the skin. The proportion
of lesions affecting sun-exposed skin areas (head and hands) was
78.8% in the immunocompetent compared with 59.5% in the
immunosuppressed patients.
Median time of non-melanoma skin lesion occurrence in renal
transplant recipients was 10.5 years (1–38) after transplantation
(SCC 6 years (1–34), BCC 9 years (2–36), SCC in situ 13 years
(2–33), and KA 15 years (1–30)). Primary immunosuppression
and immunosuppressive therapy at the time of the first non-
melanoma skin lesion is included in Table 1. No association
between type of non-melanoma skin lesion and immunosuppres-
sive treatment could be detected in the present patient cohort. In
all, 51.5% (17 out of 33) immunosuppressed patients had multiple
skin lesions (9 with 2 or 3 lesions, 6 with 4–6 lesions, and 2 with 7
lesions) which occurred either synchronously (26 out of 62 lesions)
or metachronously (36 out of 62 lesions, median time between
occurrence of lesions 1.5 years (1–7), included in Figure 2). Most
of the patients (11 out of 17, 64.7%) with multiple skin lesions had
a history of azathioprine therapy. In the cohort of immunocom-
petent patients, eight patients had two synchronous lesions.
Frequency of HR-HPV
Among all 140 analysed skin lesions including lesions from
patients with multiple tumours, mucosal HR-HPV DNA was
detected predominantly in SCC in situ and SCC with 39.0% (16 out
of 41) of SCC in situ and 33.3% (10 out of 30) of SCC. In all, 20.5%
(9 out of 44) of BCC and 6.3% (1 out of 16) of KA tested HR-HPV
positive.
Human papillomavirus DNA was detected in 29.5% (23 out
of 78) of skin lesions from immunosuppressed and in 20.9%
(13 out of 62) lesions from immunocompetent individuals
(Fisher’s exact P¼0.171). Stratification by the dermatopathology
diagnosis indicated a comparable HR-HPV prevalence between
immunosuppressed and immunocompetent patients in SCC in situ
Table 1 Demographics of renal allograft recipients (immunosuppressed)
and immunocompetent patients (median, minimum, and maximum;
number and percentage)
Renal transplant
recipients
(N¼33)
Immuno-
competent
controls
(N¼54)
Age (years) 67 (44–78) 71 (43–87)
Gender (male, %) 24 (72.7) 37 (68.5)
Time since transplantation (years) 10.5 (1–38) —
Duration of haemodialysis (years) 3 (0–15) —
Renal disease (number, %) —
Diabetes 3 (9.1)
Hypertension 3 (9.1)
Glomerulonephritis 16 (48.5)
ADPKD 4 (12.1)
Others 7 (21.2)
Transplantation —
First (number, %) 26 (78.8)
Second (number, %) 6 (18.2)
Third (number, %) 1 (3.0)
Renal allograft function
Creatinine (mgdl
 1) 1.18 (0.63–2.29)
Immunosuppression at time of transplantation/
at time of first non-melanoma skin lesion
Ciclosporin A+Azathioprin+Steroids 12/4
Azathioprin+Steroids 5/1
Ciclosporin A+Steroids 5/16
Ciclosporin A+MMF+Steroids 9/9
Tacrolimus+MMF+Steroids 2/3
Abbreviations: ADPKD¼autosomal dominant polycystic kidney disease; MMF¼myco-
phenolate mofetil.
RTX recipients with non-melanoma
skin lesions
RTX recipients (n=34)
with
histologic examination and sufficient
paraffin embedded tumour tissue
1 RTX recipients with 1 actinic keratosis
excluded from analysis
RTX recipients analysed
N=33
Total number of non-melanoma skin
lesions analysed
N=78
Immunocompetent controls analysed
N=54
Total number of non-melanoma skin
lesions analysed
N=62
Immunocompetent controls (n=54)
with
histologic examination and sufficient
paraffin embedded tumour tissue
Immunocompetent controls with non-
melanoma skin lesions
N=54 N=54
Figure 1 Study flow chart. RTX¼renal transplantation.
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sand BCC, but a slightly higher prevalence of HR-HPV in SCC
from the immunosuppressed patients (46.2% (6 out of 13) vs 23.5%
(4 out of 17)) (Table 2). High-risk human papillomavirus status in
association with immune status was independent from the strata
age, gender, and sun exposure. All HR-HPV-positive lesions were
genotyped as positive for HPV16. Multiple infections with
HR-HPV types 18, 39, 45, and/or 56 together with HPV16 were
detected in seven lesions from immunosuppressed patients (three
SCC in situ, two SCC, and two BCC) and in one lesion from the
immunocompetent group (one SCC) (Table 2).
Most (52.9%, 9 out of 17) immunosuppressed patients with
multiple skin lesions had HPV-negative and HPV-positive
tumours. In all, 35.3% (6 out of 17) had only HPV-negative
lesions (Figure 2). One immunocompetent patient with two lesions
had one HPV-negative and one HPV-positive lesion. The
remaining immunocompetent patients with two lesions (87.5%, 7
out of 8) had HPV-negative lesions only.
p16
INK4a expression and correlation with HR-HPV
A diffuse, continuous pattern of cytoplasmic and/or nuclear
p16
INK4a expression arising from basal and parabasal epithelial
cells as it is characteristic for HR-HPV-transformed mucosal
squamous epithelia was observed in 47.1% (66 out of 140) of skin
lesions, with the highest frequency in SCC in situ (92.7%, 38 out of
41). Most SCC in situ showed diffuse p16
INK4a expression
beginning in the parabasal cell layer, but no p16
INK4a expression
in the basal cell layer (Figure 3); 36.7% (11 out of 30) of the
invasive SCC, 30.2% (16 out of 53) of the BCC, and 6.7% (1 out of
15) KA showed a diffuse p16
INK4a expression pattern (Table 2;
Figure 3). Altogether, 86.1% (31 out of 36) of HR-HPV-positive
lesions demonstrated a diffuse p16
INK4a expression pattern
compared with 33.7% (35 out of 104) of HR-HPV-negative lesions
(Po0.001). In almost all SCC, BCC, and KA lesions with a diffuse
p16
INK4a expression pattern, HPV DNA was detected, whereas
Gender Age 1st tumour
SCC i.s. BCC
BCC
SCC
SCC i.s.
BCC
BCC
BCC
BCC
SCC
p53
# * # 2nd tumour 3rd tumour # 4th tumour # 5th tumour # 6th tumour # 7th tumour
p16
p16
p16
p53
HPV +
p16
p53
p16
p16
p16
p53
p53
p53 p53
p16
p53
p16
p53
p16
p53
p16
p53
p16
p53
p16
p16
p16
p16
p16
HPV +
HPV +
HPV –
HPV –
HPV –
HPV –
HPV –
HPV –
HPV –
HPV +
p53
p53
p53
p53
p53
p53
p16
S. aur. +
S. aur. +
S. aur. +
S. aur. +
S. aur. +
S. aur. +
S. aur. +
HPV –
SCC
SCC i.s.
SCC i.s.
SCC i.s.
BCC
BCC
BCC
SCC i.s.
SCC i.s.
SCC i.s.
SCC i.s.
SCC
SCC
p16
KA
BCC
HPV –
HPV –
HPV –
HPV –
HPV –
pRB
HPV –
pRB
HPV –
Male 44
71
66
1
5
1
2
9
Male
Male
53
1
0
Male
72
2
2
2
2
3
3
4
3
5
0
0
0
0
0
0
0
2
2
2
1
1
1
1
1
1
1
1
Male
67
2 Male
77
2
6
Male
64
5 Female
75
9 Female
73
8 Male
70
4 Male
52
3 Male
71
1
7
Female
59
3
0
Male
55
3 Male
62
1
7
Female
58
2 Male
p16
p53
p16
BCC
p16
p16
pRB
p16
p16
p16
pRB
pRB
pRB
HPV –
pRB
pRB
pRB
pRB pRB
pRB
pRB
pRB
S. aur. –
S. aur. –
S. aur. – S. aur. +
p53
p53
p53
p53
p53
p16
p16
p16
BCC
p53
p53
p53
p53 p53
p16
p16
p16 p16
0
0
0
4
1
1
0
0
1
7
0
0
1
1
0
0
1
2
0
p16
BCC
SCC i.s.
SCC i.s.
SCC i.s.
SCC i.s. BCC
SCC SCC
p53
p16
SCC
BCC
p16
p16
HPV +
HPV –
HPV –
HPV –
HPV –
HPV –
HPV –
S. aur. –
S. aur. –
S. aur. –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
pRB pRB pRB pRB pRB
HPV – HPV + HPV + HPV – HPV – BCC BCC BCC BCC
p53
p16
BCC
p53
p16
BCC
p53
p16
BCC
p53
p16
BCC
p53
p16
BCC
p53
p16
SCC
p53
p16
SCC
p53
p16
SCC
p53
p16
SCC i.s.
p53
p16
SCC i.s.
p53
p16
p53
p16
KA
SCC i.s.
p53
p16
SCC i.s.
p53
p16
SCC i.s.
p53
p16
BCC
p53
p16
BCC
p53
p16
BCC
p53
p16
BCC
p53
p16
BCC
p53
p16
BCC
p53
p16
BCC
S. aur. –
pRB
HPV –
S. aur. –
S. aur. –
pRB
HPV –
S. aur. –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV +
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV +
S. aur. –
pRB
HPV +
S. aur. –
pRB
pRB
HPV +
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
HPV +
S. aur. +
pRB
HPV +
S. aur. +
S. aur. – S. aur. – S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. –
pRB
HPV –
S. aur. +
pRB
HPV –
S. aur. –
p53
pRB
S. aur. –
pRB
pRB
HPV +
S. aur. +
pRB
HPV +
p53
p53
p16
p53
p53
p53
p53
p16
p53 S. aur. –
pRB
S. aur. –
pRB
S. aur. –
pRB
S. aur. –
pRB
S. aur. –
pRB
S. aur. –
S. aur. –
pRB
p53
p53
p16
S. aur. –
pRB
S. aur. –
S. aur. –
pRB
S. aur. –
pRB
S. aur. –
pRB
S. aur. – p53
S. aur. –
pRB
p16
pRB
HPV +
S. aur. +
Figure 2 Results of non-melanoma skin lesions from immunosuppressed patients with multiple tumours. Age is given at occurrence of first skin lesion.
*Time (years) between first transplantation and first skin lesion. #Time (years) between occurrence of next skin lesion. Black background indicates positive
results for HPV/S. aureus or diffuse/strong expression of p16
INK4a (diffuse)/pRB (strong)/p53 (strong). Grey background indicates moderate expression of
pRB/p53. White background indicates negativity. SCC¼squamous cell cancer; BCC¼basal cell cancer; KA¼keratoacanthoma; SCC i.s.¼SCC in situ;
p16¼p16
INK4a; S. aur.¼Staphylococcus aureus.
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snearly all SCC in situ were p16
INK4a positive, irrespective of
HR-HPV status (see Table 3 for detailed results).
pRB and p53 expression and relation to HR-HPV and
p16
INK4a
Frequency of pRB expression is provided in Table 2. In most of the
non-melanoma skin lesions positive for a diffuse p16
INK4a
expression pattern (n¼66), no pRB expression was detectable
(50 negative, 13 moderate, and 3 strong; P¼0.001).
Strong p53 expression was detected in 40.0% (56 out of 140) of
the analysed skin lesions and particularly frequent in SCC in situ
(65.9%, 27 out of 41). The frequency of strong p53 expression was
comparable between immunosuppressed and immunocompetent
patients in SCC in situ and BCC, while in invasive SCC the
frequency of a strong p53 expression was lower in immunosup-
pressed than in immunocompetent patients (7.7% (1 out of 13) vs
41.2% (7 out of 17), P¼0.04; Table 2). No association between p53
and p16
INK4a expression was observed. In all, 25.7% of all lesions
showed both, diffuse p16
INK4a, and strong p53 expression; 21.4%
showed a diffuse p16
INK4a expression pattern while lacking strong
p53 expression; 14.3% showed strong p53 expression, but no
diffuse p16
INK4a expression pattern.
Tumours from patients with multiple lesions showed hetero-
geneity for HR-HPV status, p16
INK4a, pRB, and p53 expression
(Figure 2).
Staphylococcus aureus infection
Staphylococcus aureus was detected in 30.6% (19 out of 62) non-
melanoma skin lesions from immunocompetent and in 26.9%
(21 out of 78) from immunosuppressed patients (P¼0.38).
Altogether, 30.0% (9 out of 30) SCC, 18.9% BCC (10 out of 53),
30% SCC in situ (16 out of 41), and 45.5% (5 out of 11) KA were
positive for S. aureus (Table 2).
DISCUSSION
Human papillomavirus DNA, including HR-HPV types known to
cause anogenital and a proportion of head and neck cancers, has
been repeatedly detected in NMSC (de Villiers et al, 1997) and
non-invasive epithelial skin lesions. From studies in anogenital
and head and neck cancers it is well known that HR-HPV
oncogenes, once they are expressed, interact with cellular cell cycle
regulators and contribute to uncontrolled cell proliferation, most
importantly by degradation of pRB and p53 (Scheffner et al, 1990).
p16
INK4a is expressed strongly and continuously in cells under-
going HR-HPV-mediated transformation in epithelia of the uterine
cervix. Though the mechanism is not fully clear, there is evidence
that a negative feedback mechanism controlling p16
INK4a levels in
normal cells is disrupted by a reduction of pRB activity in cells
expressing HR-HPV oncogene E7 (Khleif et al, 1996). Also some
other cancer types, irrespective of the HPV status, show an inverse
correlation between pRB and p16
INK4a expression levels (Okamoto
et al, 1994; Geradts et al, 1995).
In the present systematic explorative study, we demonstrated
that mucosal HR-HPV DNA (HPV16) can be detected in
keratinised squamous epithelium, at a frequency of 23–46% in
analysed SCC in situ and invasive SCC and 11–20% in BCC. This
finding is in line with previous reports, although frequencies
varied between 2% and 50%, which is most likely due to different
HPV detection methods (Harwood et al, 2000; Iftner et al, 2003;
Nindl et al, 2004).
Table 2 Results of HR-HPV detection, p16
INK4a, pRB, p53 expression analysis, and Staphylococcus aureus detection in all 140 analysed skin lesions from
renal transplant recipients and immunocompetent patients
Lesions from renal transplant recipients Lesions from immunocompetent patients
SCC in situ SCC BCC KA SCC in situ SCC BCC KA
n % n % n % n % n % n % n % n %
Total n 24 13 35 6 17 17 18 10
HR-HPV
Negative 15 62.5 7 53.8 28 80.0 5 83.3 10 58.8 13 76.5 16 88.9 10 100.0
Positive 9 37.5 6 46.2 7 20.0 1 16.7 7 41.2 4 23.5 2 11.1 0 0.0
1 HPV type 6 25.0 4 30.8 5 14.3 1 16.7 7 41.2 3 17.6 2 11.1 0 0.0
2–3 HPV types 1 4.2 2 15.4 2 5.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
43 HPV types 2 8.3 0 0.0 0 0.0 0 0.0 0 0.0 1 5.9 0 0.0 0 0.0
p16
INK4a
No expression 1 4.2 0 0.0 3 8.6 1 16.7 2 11.8 1 5.9 0 0.0 0 0.0
Focal 0 0.0 7 53.8 22 62.9 4 66.7 0 0.0 11 64.7 12 66.7 10 100.0
Diffuse 23 95.8 6 46.2 10 28.6 1 16.7 15 88.2 5 29.4 6 33.3 0 0.0
pRB
No expression 18 75.0 6 46.2 15 42.9 1 16.7 14 82.4 8 47.1 13 72.2 7 70.0
Moderate 5 20.8 7 53.8 12 34.3 4 66.7 2 11.8 9 52.9 5 27.8 3 30.0
Strong 1 4.2 0 0.0 8 22.9 1 16.7 1 5.9 0 0.0 0 0.0 0 0.0
p53
No expression 5 20.8 6 46.2 12 34.3 2 33.3 3 17.6 4 23.5 9 50.0 8 80.0
Moderate 3 12.5 6 46.2 10 28.6 3 50.0 3 17.6 6 35.3 2 11.1 2 20.0
Strong 16 66.7 1 7.7 13 37.1 1 16.7 11 64.7 7 41.2 7 38.9 0 0.0
Staphylococcus aureus
Negative 16 16.7 9 69.2 27 77.1 5 83.3 9 52.9 12 70.6 16 88.9 6 60.0
Positive 8 33.3 4 30.8 8 22.9 1 16.7 8 47.1 5 29.4 2 11.1 4 40.0
Abbreviations: SCC¼squamous cell cancer; BCC¼basal cell cancer; KA¼keratoacanthoma; HR-HPV¼high-risk human papillomavirus.
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sWe observed a strong correlation between HR-HPV positivity
and diffuse p16
INK4a expression in invasive SCC and BCC. Most
p16
INK4a-positive lesions lacked pRB expression. Although this
observational study cannot formally prove a transforming role of
HR-HPV, the finding of frequent pRB absence and p16
INK4a
overexpression in HR-HPV-positive SCC and BCC might suggest a
potential relevance of HR-HPV in NMSC. Basal epithelial cells in
SCC in situ often lacked p16
INK4a and p53 expression. This finding
might be compatible with the assumption that the basal cells are
most likely not involved in SCC in situ carcinogenesis (Ishida et al,
2001). Although HR-HPV could be detected in a proportion of SCC
in situ, mechanisms other than HR-HPV might cause a non-
functional pRB pathway and thus be responsible for p16
INK4a
overexpression and absence of pRB expression.
Strong p53 expression was observed in 40% of the analysed
tumours irrespective of HPV status. This observation might
suggest presence of mutations in the p53 tumour suppressor gene
in these tumours, as p53 overexpression has been linked to certain
p53 mutations (Benjamin et al, 2008; Kusters-Vandevelde et al,
2010). However, a high level of detectable p53 protein has also
been observed without detectable p53 mutations (Stark et al, 1994).
There is evidence from the literature that p53 overexpression
(and p53 mutations) and HR-HPV positivity are inversely
correlated in oropharyngeal and vulvar cancer, which led to the
classification of molecularly distinct tumour entities (HR-HPV
positive/p53 expression negative and HR-HPV negative/p53
expression positive) that also show marked differences in their
clinical behaviour (Kruse et al, 2008; Smith et al, 2008), though p53
has also been found strongly expressed in some HR-HPV
transformed cancer cells (Cheah and Looi, 2002). Based on our
data, there is no correlation between p53 expression and HR-HPV
status in epithelial skin lesions. Thus, it may well be that in skin
p16INK4a
p16INK4a
pRB p53
pRB p53
p16INK4a pRB p53
Figure 3 Immunohistochemical staining of serial tissue sections from non-melanoma skin lesions for p16
INK4a, pRB, and p53. (A–C) HR-HPV-positive
SCC in situ with diffuse p16
INK4a expression pattern (A), absence of pRB expression (B), and strong p53 expression (C). Note the absence of p16
INK4a, pRB,
and p53 expression in the basal cell layer of this SCC in situ.( D–F) HR-HPV-positive invasive SCC with diffuse p16
INK4a expression pattern (D), weak pRB
expression (E), and absence of p53 expression (F). (G–I) HR-HPV-negative BCC with absence of diffuse p16
INK4a expression, moderate pRB expression,
and strong p53 expression.
Table 3 HR-HPV infection and diffuse p16
INK4a expression pattern in non-melanoma skin lesions from renal transplant recipients and immunocompetent
controls
Renal transplant recipients NMSC lesions (N¼78) Immunocompetent controls NMSC lesions (N¼62)
HR-HPV+ HR-HPV  HR-HPV+ HR-HPV 
p16
INK4a+ p16
INK4a  p16
INK4a + p16
INK4a  P p16
INK4a+ p16
INK4a  p16
INK4a+ p16
INK4a  P
SCC 5 1 1 6 o0.05 4 0 1 12 o0.001
BCC 4 3 6 22 0.06 2 0 4 12 o0.05
SCC in situ 9 0 14 1 NS 6 1 9 1 NS
KA 1 0 0 5 o0.05 0 0 0 10 —
All lesions 19 4 21 34 o0.001 12 1 14 35 o0.001
Abbreviations: SCC¼squamous cell cancer; BCC¼basal cell cancer; KA¼keratoacanthoma; HR-HPV¼high-risk human papillomavirus; NMSC¼non-melanoma skin cancer.
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of p53 is not as important as in the pathogenesis of known HR-
HPV-associated cancers and p53 mutations or other genetic/
epigenetic alterations have a primary role in skin carcinogenesis.
HPV might then be an additional factor contributing to malignant
transformation of the skin. Interestingly, we and others (Blokx
et al, 2003; Kusters-Vandevelde et al, 2009) found a lower
frequency of p53 overexpression in invasive SSC from immuno-
suppressed compared with immunocompetent patients. The
biological and clinical relevance of this finding needs to be
addressed on larger patient cohorts.
The status of p16
INK4a, pRB, and p53 expression was discordant
among multiple tumours from the same patient, suggesting
varying carcinogenic modes or stages. Inter-tumoural diversity
was also found regarding HR-HPV status – most patients with
multiple tumours had both, HR-HPV-positive and -negative
tumours. Nevertheless, clonality of HR-HPV-positive tumours
should be assessed in future studies.
Besides viral infection, bacterial colonisation of the skin might
contribute to a higher incidence of skin lesions in the immuno-
suppressed. The prevalence of S. aureus has been reported to be
higher in skin SCC than in BCC or normal skin (Kullander et al,
2009). In our cohort, S. aureus DNA was detected in over 30% of
invasive SCC and SCC in situ and, less frequently, in BCC. This
also applied to the group of immunosuppressed patients. Presence
of S. aureus in NMSC might simply indicate an increased
susceptibility for bacterial colonisation of neoplastically altered
skin. On the other hand, a pathogenetic role of S. aureus cannot be
excluded, as bacteria might contribute to carcinogenesis by
inducing chronic inflammation.
In contrast to the higher prevalence of SCC than BCC reported
for transplant recipients (Euvrard et al, 2003), the prevalence of
BCC was higher than SCC in our cohort. Also, patients who were
excluded from the study were more likely to have BCC than SCC
(data not shown). Regular systematic dermatology evaluations and
non-surgical therapy for keratotic skin lesions might explain the
relatively low prevalence of invasive SCC in our cohort. Moreover,
in our hospital an early low-dose calcineurin inhibitor regimen has
been established which might affect tumour prevalence in so far as
high-dose calcineurin inhibitor regimens are supposed to increase
the risk of especially SCC (Wu et al, 2010).
In summary, we conclude that HR-HPV DNA is detectable in
keratinised skin and might contribute to skin cancer pathogenesis in
a proportion of lesions. High-risk human papillomavirus prevalence
in invasive skin SCC tended to be slightly higher in immunosup-
pressed than in immunocompetent patients. Further studies are
warranted on the relevance of HPV in NMSC carcinogenesis,
especially with regard to a potential beneficial effect of prophylactic
HPV vaccines in skin cancer prevention, which would be
particularly important in organ transplant recipients.
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